Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Urinary albumin excretion of ≤3000 μg of creatinine~2. Stage 3 CKD~3. Plasma iPTH: \> 70 pg/mL and \< 500 pg/mL~4. Serum Ca: ≥ 8.4 mg/dL and \< 10.0 mg/dL~5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL~6. Serum 25-hydroxyvitamin D: \> 10 ng/mL and \< 29 ng/mL.~7. Discontinue vitamin D use for duration of study~Exclusion Criteria:~1. History of kidney transplant or parathyroidectomy~2. Spot urine calcium:creatinine ratio \> 0.2~3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis~4. Currently on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CTAP101 Capsules 60µg (Type: EXPERIMENTAL): None
- Cohort 1: CTAP101 Capsules 90µg (Type: EXPERIMENTAL): None
- Cohort 1: Sugar Capsule (Type: PLACEBO_COMPARATOR): None
- Cohort 2: CTAP101 Capsules 30µg (Type: EXPERIMENTAL): None
- Cohort 2: Sugar Capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).